media – Page 550 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics

Orthotaxy’s Technology Will Be Leveraged to Develop Cost-Effective, Time-Efficient, User-Friendly Offering in a Broad Range of Orthopaedics Procedures.
- Source: Jnj
- 520
- February 27, 2018
Market Views Orthopaedics
Researchers develop new technology platform for cancer immunotherapy

Johns Hopkins researchers have invented a new class of immunotherapeutic agents that are more effective at harnessing the power of the immune system to fight cancer. Their approach results in significant inhibition of tumor growth, even against cancers which do not respond to existing immunotherapies used in the clinic. In collaboration with Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery, the team reports their results this week in Nature Communications.
- Source: immunotherapies
- 516
- February 27, 2018
cancer immunotherapies Researches
XOC PHARMACEUTICALS ANNOUNCES $30 MILLION SERIES A FINANCING LED BY NEA

Company to move forward with novel therapies for migraine and Parkinson’s disease
- Source: xocpharma
- 541
- February 27, 2018
CNS migraine Parkinson’s disease Series
Kardian’s contactless monitoring system detects falls

It looks like a simple fire alarm, but instead of detecting smoke the Kardian Contactless Health Monitoring System is designed to detect falls.
- Source: mobihealthnews
- 648
- February 27, 2018
Company Insight healthcare technologies and innovations medical device
UK’s NHS Aims to Build a Library of Reliable Mobile Health Apps.

The UK's National Health Service is putting out the call for more mobile health apps for its NHS Apps Library, and has chosen an agency to certify those apps. The library now features 46 mHealth apps - only one of which has passed muster.
- Source: mHealth Intelligence
- 648
- February 27, 2018
Company Insight digital health mHealth
Cedars-Sinai, Emulate partner to give precision medicine a boost with organs-on-chips tech

The technology could enable researchers to test drugs or treatments on a patient’s cells to avoid harmful, ineffective and costly options while determining personalized regimens.
- Source: Healthcare IT News
- 546
- February 27, 2018
digital health medtech precision medicine Researches
Gilead links with Sangamo in gene therapy alliance

Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
- Source: drugdu
- 543
- February 26, 2018
cancer engineered cell therapies Gilead Market Views
AI Biotech XtalPi Closes Series B Round Funding from Sequoia China, Google, and Tencent

XtalPi Inc., a computation-driven pharmaceutical technology company, announced that it has closed a Series B funding round of 15 million USD led by Sequoia China, with participation from Google and existing investor Tencent. To date, XtalPi has raised over 20 million USD, making it one of the top-funded AI-powered biotechs.
- Source: finance.yahoo
- 519
- February 26, 2018
biotechs Market Views Series
Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

Merck & Company is driving forward in its quest to develop a premier immuno-oncology pipeline. The company plunked down $394 million to acquire Australia-based Viralytics Ltd and its oncolytic immunotherapy treatments.
- Source: Biospace;
- 723
- February 26, 2018
immuno-oncology pipelin immunotherapy Market Views Merk
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Gilead Sciences, Inc.(NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available.
- Source: gilead
- 901
- February 26, 2018
Biktarvy FDA Gilead Sciences HIV-1 infection

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.